Connor, Clark & Lunn Investment Management (CC&L)
ALXO icon

Connor, Clark & Lunn Investment Management (CC&L)’s ALX Oncology ALXO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-83,042
Closed -$151K – 1400
2024
Q3 		$151K Buy
83,042
+56,028
+207% +$208K ﹤0.01% 1348
2024
Q2 		$163K Sell
27,014
-2,070
-7% -$25.5K ﹤0.01% 1280
2024
Q1 		$324K Buy
29,084
+15,775
+119% +$222K ﹤0.01% 1238
2023
Q4 		$198K Buy
+13,309
New +$126K ﹤0.01% 1264

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ALXO Position: Q4 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of ALX Oncology (ALXO) in Q4 2024, closing a stake of 83,042 shares — an estimated $151K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ALXO in Q4 2023 and held it in 4 quarters. The position peaked at $324K in Q1 2024. 87 funds tracked by Wall St. Rank hold ALXO as of Q4 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining ALX Oncology position as of Q4 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 83,042 ALX Oncology shares in Q4 2024, an estimated $151K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ALX Oncology in Q4 2023 and held it in 4 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s ALX Oncology position peaked at $324K in Q1 2024.
  • 87 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2024, filed 10 Feb 2025.